Literature DB >> 357875

Decreased vascular prostacyclin in experimental diabetes.

H E Harrison, A H Reece, M Johnson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 357875     DOI: 10.1016/0024-3205(78)90020-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  23 in total

1.  Changes in cardiovascular sensitivity of alloxan-treated diabetic rats to arachidonic acid.

Authors:  A L Boura; W C Hodgson; R G King
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

Review 2.  Molecular insights and therapeutic targets for diabetic endothelial dysfunction.

Authors:  Jian Xu; Ming-Hui Zou
Journal:  Circulation       Date:  2009-09-29       Impact factor: 29.690

Review 3.  Physiology and pharmacology of prostaglandins.

Authors:  S J Konturek; W Pawlik
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

4.  Renal vascular responsiveness to arachidonic acid in experimental diabetes.

Authors:  J Quilley; J C McGiff
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

5.  The evolution of diabetic retinopathy.

Authors:  E V Kohner
Journal:  Ir J Med Sci       Date:  1979       Impact factor: 1.568

6.  Platelet aggregability during the first two years of type 1 (insulin-dependent) diabetes mellitus in children.

Authors:  A M Kobbah; U Ewald; T Tuvemo
Journal:  Diabetologia       Date:  1989-10       Impact factor: 10.122

7.  Differential changes of adrenoceptor- and muscarinic receptor-linked prostacyclin synthesis by the aorta and urinary bladder of the diabetic rat.

Authors:  J Y Jeremy; C S Thompson; D P Mikhailidis
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

8.  Influence of glucose, insulin and sera from diabetic patients on the prostacyclin synthesis in vitro in cultured human endothelial cells.

Authors:  S Aanderud; H Krane; A Nordøy
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

9.  Is the variation in the susceptibility of various species to atherosclerosis due to inborn differences in prostacyclin (PGI2) formation.

Authors:  H Sinzinger; P Clopath; K Silberbauer; M Winter
Journal:  Experientia       Date:  1980-03-15

10.  Effect of insulin treatment on prostacyclin in experimental diabetes.

Authors:  H E Harrison; A H Reece; M Johnson
Journal:  Diabetologia       Date:  1980-01       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.